<p>根據最近向證券交易委員會（SEC）提交的文件，Colonial Trust Advisors 在第四季度將其在史賽克（Stryker Co.，NYSE:SYK - 免費報告）股票中的持倉減少了 2.5%。該基金在出售了 760 股後，持有 29,404 股這家醫療技術公司的股票。截至其最近向證券交易委員會（SEC）提交的文件，Colonial Trust Advisors 在史賽克的持股價值為 10,587,000 美元。</p>
<ul>
<li>如果你只能持有 3 項投資一輩子，請考慮這些</li>
</ul>
<p>其他一些對沖基金和機構投資者最近也對 SYK 的持倉進行了調整。Kohmann Bosshard Financial Services LLC 在第四季度購買了價值約 25,000 美元的史賽克新股份。Rakuten Securities Inc.在第四季度將其在史賽克的持股增加了 618.2%。Rakuten Securities Inc.現在擁有 79 股這家醫療技術公司的股票，價值 28,000 美元，此前在上個季度又收購了 68 股。Centricity Wealth Management LLC 在第四季度購買了價值 30,000 美元的史賽克新股份。BankPlus Trust Department 在第四季度購買了價值 33,000 美元的史賽克新持倉。最後，Activest Wealth Management 在第四季度購買了價值約 36,000 美元的史賽克新持倉。77.09% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>內部買賣</h2>
<p>在其他消息中，董事 Ronda E. Stryker 在 1 月 31 日星期五出售了 201,392 股股票。股票以平均價格 392.24 美元出售，總交易額為 78,993,998.08 美元。出售完成後，該董事現在直接擁有 3,642,075 股公司股票，價值 1,428,567,498 美元。這代表其持股減少了 5.24%。該交易在向 SEC 的文件中披露，相關信息可通過 SEC 網站獲取。此外，董事 Allan C. Golston 在 2 月 18 日星期二出售了 2,458 股股票。股票以平均價格 383.07 美元出售，總交易額為 941,586.06 美元。交易完成後，該董事現在直接擁有 14,895 股公司股票，價值約 5,705,827.65 美元。這代表其持股減少了 14.16%。該銷售的披露信息可以在這裏找到。5.90% 的股票由公司內部人士持有。</p>
<h2>華爾街分析師預測增長</h2>
<ul>
<li>3 只幫助將人工智能引入醫療保健的股票</li>
</ul>
<p>一些券商最近對 SYK 發佈了報告。JMP Securities 在 2 月 18 日的研究報告中重申了對史賽克股票的 “市場表現” 評級。Needham &amp; Company LLC 在 3 月 21 日的研究報告中重新發布了 “買入” 評級，並設定了 442.00 美元的目標價。Canaccord Genuity Group 將史賽克的目標價從 420.00 美元提高到 435.00 美元，並在 1 月 29 日的研究報告中給予該公司 “買入” 評級。Truist Financial 在 1 月 30 日的報告中將史賽克的目標價從 409.00 美元提高到 413.00 美元，並給予該股票 “持有” 評級。最後，Wells Fargo &amp; Company 在 1 月 29 日的報告中將史賽克的目標價從 427.00 美元提高到 435.00 美元，並給予該公司 “增持” 評級。五位分析師對該股票給予了持有評級，十六位分析師對該公司給予了買入評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “適度買入”，共識目標價為 421.90 美元。</p>
<p><strong>查看我們最新的史賽克股票報告</strong></p>
<h2>史賽克股票上漲 7.7%</h2>
<ul>
<li>史賽克的收購狂潮：雙位數增長在望</li>
</ul>
<p>週四，SYK 的開盤價為 363.44 美元。該股票的市值為 1387.2 億美元，市盈率為 46.84，市盈增長比率為 2.93，貝塔係數為 0.93。史賽克的 12 個月低點為 314.93 美元，12 個月高點為 406.19 美元。該公司的 50 日簡單移動平均線為 377.27 美元，200 日簡單移動平均線為 373.71 美元。該公司的流動比率為 1.95，速動比率為 1.32，債務與股本比率為 0.59。</p>
<p>史賽克（NYSE:SYK - 獲取免費報告）最近在 1 月 28 日星期二宣佈了其季度財報。這家醫療技術公司報告第四季度每股收益（EPS）為 4.01 美元，超出分析師共識預期的 3.87 美元，超出幅度為 0.14 美元。史賽克的淨利潤率為 13.25%，股本回報率為 23.58%。去年同期，該公司每股收益為 3.46 美元。整體來看，研究分析師預計史賽克在當前財年將發佈 13.47 美元的每股收益。</p>
<h2>史賽克宣佈分紅</h2>
<p>該公司最近還披露了季度分紅，將於 4 月 30 日星期三支付。3 月 31 日星期一的登記投資者將獲得每股 0.84 美元的分紅。這相當於年化分紅 3.36 美元，收益率為 0.92%。該分紅的除息日期為 3 月 31 日星期一。史賽克的分紅支付比率為 43.30%。</p>
<h2>史賽克簡介</h2>
<p>（免費報告）</p>
<p>史賽克公司作為一家醫療技術公司運營。該公司通過兩個部門運營，分別是醫療外科和神經技術，以及骨科和脊柱。骨科和脊柱部門提供用於全關節置換手術的植入物，如髖關節、膝關節和肩關節，以及創傷和四肢手術。</p>
<h2>進一步閲讀</h2>
<ul>
<li>五隻我們更看好的股票，勝過史賽克</li>
<li>內部買入解釋：投資者需要知道的事項</li>
<li>First Solar 股票：是什麼推動了四月初的反彈？</li>
<li>ETF 篩選器：用途和逐步指南</li>
<li>為什麼分析師在財報前提升了聯合航空股票</li>
<li>低市盈率增長股票：解鎖投資機會</li>
<li>Dave &amp; Buster’s 股票：第二季度的短期擠壓機會</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNZSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNZSw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在史賽克嗎？</h2>
<p>在考慮史賽克之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄向客户推薦在更廣泛的市場注意到之前購買……而史賽克並不在名單上。</p>
<p>儘管史賽克目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

史賽克

<p>殖民信託顧問在第四季度將其在史賽克（NYSE:SYK）的持股減少了 2.5%，目前持有 29,404 股，估值約為 1059 萬美元。其他機構投資者也調整了他們的持倉。值得注意的是，董事 Ronda E. Stryker 出售了超過 201,000 股，減少了她的持股比例 5.24%。分析師對史賽克維持 “適度買入” 的共識，目標價為 421.90 美元。該股票開盤價為 363.44 美元，市值為 1387.2 億美元，最近的每股收益為 4.01 美元，超出預期</p>

<p>Colonial Trust Advisors trimmed its position in shares of Stryker Co. (NYSE:SYK - Free Report) by 2.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 29,404 shares of the medical technology company's stock after selling 760 shares during the quarter. Colonial Trust Advisors' holdings in Stryker were worth $10,587,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>根據最近向證券交易委員會（SEC）提交的文件，Colonial Trust Advisors 在第四季度將其在史賽克（Stryker Co.，NYSE:SYK - 免費報告）股票中的持倉減少了 2.5%。該基金在出售了 760 股後，持有 29,404 股這家醫療技術公司的股票。截至其最近向證券交易委員會（SEC）提交的文件，Colonial Trust Advisors 在史賽克的持股價值為 10,587,000 美元。</p>
</div><ul>
<li>If You Could Only Hold 3 Investments for Life, Consider These</li>
</ul>
<div class="lb-trans"><ul>
<li>如果你只能持有 3 項投資一輩子，請考慮這些</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors also recently made changes to their positions in SYK. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Stryker in the fourth quarter worth about $25,000. Rakuten Securities Inc. boosted its holdings in Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after acquiring an additional 68 shares in the last quarter. Centricity Wealth Management LLC bought a new stake in Stryker in the fourth quarter valued at $30,000. BankPlus Trust Department purchased a new position in Stryker during the fourth quarter valued at $33,000. Finally, Activest Wealth Management purchased a new position in shares of Stryker in the 4th quarter worth about $36,000. 77.09% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他一些對沖基金和機構投資者最近也對 SYK 的持倉進行了調整。Kohmann Bosshard Financial Services LLC 在第四季度購買了價值約 25,000 美元的史賽克新股份。Rakuten Securities Inc.在第四季度將其在史賽克的持股增加了 618.2%。Rakuten Securities Inc.現在擁有 79 股這家醫療技術公司的股票，價值 28,000 美元，此前在上個季度又收購了 68 股。Centricity Wealth Management LLC 在第四季度購買了價值 30,000 美元的史賽克新股份。BankPlus Trust Department 在第四季度購買了價值 33,000 美元的史賽克新持倉。最後，Activest Wealth Management 在第四季度購買了價值約 36,000 美元的史賽克新持倉。77.09% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣</h2>
</div><p>In other news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他消息中，董事 Ronda E. Stryker 在 1 月 31 日星期五出售了 201,392 股股票。股票以平均價格 392.24 美元出售，總交易額為 78,993,998.08 美元。出售完成後，該董事現在直接擁有 3,642,075 股公司股票，價值 1,428,567,498 美元。這代表其持股減少了 5.24%。該交易在向 SEC 的文件中披露，相關信息可通過 SEC 網站獲取。此外，董事 Allan C. Golston 在 2 月 18 日星期二出售了 2,458 股股票。股票以平均價格 383.07 美元出售，總交易額為 941,586.06 美元。交易完成後，該董事現在直接擁有 14,895 股公司股票，價值約 5,705,827.65 美元。這代表其持股減少了 14.16%。該銷售的披露信息可以在這裏找到。5.90% 的股票由公司內部人士持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><ul>
<li>3 Stocks Helping to Bring AI to Healthcare</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只幫助將人工智能引入醫療保健的股票</li>
</ul>
</div><p>A number of brokerages recently issued reports on SYK. JMP Securities reiterated a &#34;market perform&#34; rating on shares of Stryker in a research note on Tuesday, February 18th. Needham &amp; Company LLC reissued a &#34;buy&#34; rating and set a $442.00 price target on shares of Stryker in a research report on Friday, March 21st. Canaccord Genuity Group increased their price target on Stryker from $420.00 to $435.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, January 29th. Truist Financial raised their target price on Stryker from $409.00 to $413.00 and gave the stock a &#34;hold&#34; rating in a report on Thursday, January 30th. Finally, Wells Fargo &amp; Company raised their price objective on Stryker from $427.00 to $435.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $421.90.</p>
<div class="lb-trans"><p>一些券商最近對 SYK 發佈了報告。JMP Securities 在 2 月 18 日的研究報告中重申了對史賽克股票的 “市場表現” 評級。Needham &amp; Company LLC 在 3 月 21 日的研究報告中重新發布了 “買入” 評級，並設定了 442.00 美元的目標價。Canaccord Genuity Group 將史賽克的目標價從 420.00 美元提高到 435.00 美元，並在 1 月 29 日的研究報告中給予該公司 “買入” 評級。Truist Financial 在 1 月 30 日的報告中將史賽克的目標價從 409.00 美元提高到 413.00 美元，並給予該股票 “持有” 評級。最後，Wells Fargo &amp; Company 在 1 月 29 日的報告中將史賽克的目標價從 427.00 美元提高到 435.00 美元，並給予該公司 “增持” 評級。五位分析師對該股票給予了持有評級，十六位分析師對該公司給予了買入評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “適度買入”，共識目標價為 421.90 美元。</p>
</div><p><strong>View Our Latest Stock Report on Stryker</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的史賽克股票報告</strong></p>
</div><h2>Stryker Trading Up 7.7 %</h2>
<div class="lb-trans"><h2>史賽克股票上漲 7.7%</h2>
</div><ul>
<li>Stryker’s Acquisition Spree: Double-Digit Growth on the Horizon</li>
</ul>
<div class="lb-trans"><ul>
<li>史賽克的收購狂潮：雙位數增長在望</li>
</ul>
</div><p>SYK opened at $363.44 on Thursday. The stock has a market capitalization of $138.72 billion, a P/E ratio of 46.84, a P/E/G ratio of 2.93 and a beta of 0.93. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The firm's fifty day simple moving average is $377.27 and its 200 day simple moving average is $373.71. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.</p>
<div class="lb-trans"><p>週四，SYK 的開盤價為 363.44 美元。該股票的市值為 1387.2 億美元，市盈率為 46.84，市盈增長比率為 2.93，貝塔係數為 0.93。史賽克的 12 個月低點為 314.93 美元，12 個月高點為 406.19 美元。該公司的 50 日簡單移動平均線為 377.27 美元，200 日簡單移動平均線為 373.71 美元。該公司的流動比率為 1.95，速動比率為 1.32，債務與股本比率為 0.59。</p>
</div><p>Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the company posted $3.46 EPS. As a group, research analysts anticipate that Stryker Co. will post 13.47 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>史賽克（NYSE:SYK - 獲取免費報告）最近在 1 月 28 日星期二宣佈了其季度財報。這家醫療技術公司報告第四季度每股收益（EPS）為 4.01 美元，超出分析師共識預期的 3.87 美元，超出幅度為 0.14 美元。史賽克的淨利潤率為 13.25%，股本回報率為 23.58%。去年同期，該公司每股收益為 3.46 美元。整體來看，研究分析師預計史賽克在當前財年將發佈 13.47 美元的每股收益。</p>
</div><h2>Stryker Announces Dividend</h2>
<div class="lb-trans"><h2>史賽克宣佈分紅</h2>
</div><p>The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date of this dividend is Monday, March 31st. Stryker's dividend payout ratio is 43.30%.</p>
<div class="lb-trans"><p>該公司最近還披露了季度分紅，將於 4 月 30 日星期三支付。3 月 31 日星期一的登記投資者將獲得每股 0.84 美元的分紅。這相當於年化分紅 3.36 美元，收益率為 0.92%。該分紅的除息日期為 3 月 31 日星期一。史賽克的分紅支付比率為 43.30%。</p>
</div><h2>Stryker Profile</h2>
<div class="lb-trans"><h2>史賽克簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.</p>
<div class="lb-trans"><p>史賽克公司作為一家醫療技術公司運營。該公司通過兩個部門運營，分別是醫療外科和神經技術，以及骨科和脊柱。骨科和脊柱部門提供用於全關節置換手術的植入物，如髖關節、膝關節和肩關節，以及創傷和四肢手術。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Stryker</li>
<li>Insider Buying Explained: What Investors Need to Know</li>
<li>First Solar Stock: What's Fueling the Early April Rally?</li>
<li>ETF Screener: Uses and Step-by-Step Guide</li>
<li>Why Analysts Boosted United Airlines Stock Ahead of Earnings</li>
<li>Low PE Growth Stocks: Unlocking Investment Opportunities</li>
<li>Dave &amp; Buster’s Stock: A Short-Squeeze PLAY for Q2</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過史賽克</li>
<li>內部買入解釋：投資者需要知道的事項</li>
<li>First Solar 股票：是什麼推動了四月初的反彈？</li>
<li>ETF 篩選器：用途和逐步指南</li>
<li>為什麼分析師在財報前提升了聯合航空股票</li>
<li>低市盈率增長股票：解鎖投資機會</li>
<li>Dave &amp; Buster’s 股票：第二季度的短期擠壓機會</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNZSw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=SYK"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Stryker Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在史賽克嗎？</h2>
</div><p>Before you consider Stryker, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮史賽克之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄向客户推薦在更廣泛的市場注意到之前購買……而史賽克並不在名單上。</p>
</div><p>While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管史賽克目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Colonial Trust Advisors 在史賽克公司（NYSE:SYK）持有 1059 萬美元的頭寸